AriBio to unveil results at the U.S. CTAD conference on the 17th; HLB Therapeutics expected to announce findings next week.
A watershed moment for global drug commercialization; will this trigger a revaluation of K-Bio?
The South Korean biotech industry is facing a significant turning point in global drug development. AriBio’s oral Alzheimer’s disease candidate, 'AR1001', and HLB Therapeutics' neurotrophic keratitis (NK) candidate, 'RGN-259', are both nearing the release of their global Phase 3 clinical trial results.
Both companies have led late-stage global trials and are actively preparing for commercialization, including pursuing overseas licensing agreements and partnerships with global pharmaceutical firms. These results are expected to serve as a litmus test for the global drug development capabilities of the K-Bio sector, extending beyond the commercial potential of the individual companies.
The Challenge of Oral Dementia Treatment: AriBio’s $4.7 Billion Licensing Milestone
AriBio is set to present the results of its global Phase 3 'POLARIS-AD' trial for AR1001 at the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference in Boston on October 17 at 6:05 AM (KST).
The trial involved 1,535 patients with early-stage Alzheimer’s across 13 countries, including South Korea, the U.S., and Europe, with 1,348 participants (87.8%) completing the 52-week study.
The key focus is whether the drug can demonstrate a delay in cognitive and functional decline compared to the placebo group, as measured by the primary endpoint, the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Beyond statistical significance, the magnitude of the therapeutic effect, the delay in impairment of daily living activities, and safety profiles remain critical.
Fred Kim, head of AriBio’s U.S. branch, emphasized that the company is focused on the efficacy of the monotherapy and the tangible benefits experienced by patients. The strategy is to position AR1001 as a first-line treatment for early Alzheimer’s, leveraging its convenience and price competitiveness.
Commercially, the spotlight is on the global licensing option agreement with China’s Fosun Pharma, valued at up to $4.74 billion (approximately 7 trillion KRW), covering major markets including the U.S., Europe, and Japan.
Following the receipt of a $60 million option fee in July and an additional 11.5 billion KRW in equity investment in October, positive Phase 3 results are expected to accelerate the exercise of licensing options by Fosun Pharma and the pursuit of FDA approval, with the company targeting a 2027 filing and 2028 approval.
Overcoming European Setbacks: HLB Therapeutics Targets the $2 Billion U.S. Market
HLB Therapeutics is awaiting the results of the 'SEER-2' global Phase 3 trial for RGN-259, conducted through its U.S. subsidiary, ReGenTree.
The company officially announced the completion of the trial across 50 medical institutions in August. The top-line results from the Contract Research Organization (CRO) are expected in mid-November, and the company plans to disclose them immediately upon receipt.
RGN-259 failed to achieve statistical significance in its primary endpoint during the European Phase 3 (SEER-3) trial last June. The success of this trial hinges on demonstrating a significant difference in the complete corneal epithelial healing rate compared to the placebo group after four weeks of treatment.
Ahn Ki-hong, CEO of HLB Therapeutics, stated that the company applied stricter patient selection criteria and enhanced the quality verification of corneal imaging compared to the European trial. Following the results, the company plans to consult with the FDA on the necessity of additional confirmatory trials and continue business discussions with global pharmaceutical companies.
The existing NK treatment, 'Oxervate', recorded $1.724 billion (approximately 2.3 trillion KRW) in U.S. sales last year before discounts and rebates. RGN-259 aims to penetrate the U.S. market with advantages such as room-temperature storage and a shorter four-week treatment duration.
Beyond Clinical Completion: A Litmus Test for K-Bio
Historically, the valuation of South Korean biotech firms has often been driven by early-stage clinical achievements and licensing deals. The Phase 3 trials of these two companies serve as a milestone to determine whether domestic firms can lead global late-stage trials and successfully navigate the path to commercialization.
Positive outcomes for both companies could improve investor sentiment across the broader K-Bio sector, particularly for other firms holding late-stage global pipelines. As the KOSDAQ market seeks new growth drivers following a period of semiconductor-heavy volatility, the biotech sector is under close observation. However, for expectations to translate into sustained corporate value, success must be backed by subsequent regulatory approvals, technology transfers, and commercial performance.
The global Phase 3 trials have been completed. Now, it is time for the data to prove the value of these new drugs.
